Latest Mapatumumab Stories
QUEBEC CITY, April 22 /PRNewswire-FirstCall/ - AEterna Zentaris Inc.
- Findings Demonstrate Survival Benefit with Picoplatin as Second-Line Therapy for Small Cell Lung Cancer - SOUTH SAN FRANCISCO, Calif., April 20 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc.
- Updated Data from Initial Cohort Shows 11 of 17 Evaluable Patients Receiving Bavituximab in Combination with Carboplatin + Paclitaxel Achieved an Objective Tumor Response - - Patient Dosing Initiated in Expansion Stage of Trial with Target of Enrolling 49 Patients Overall - TUSTIN, Calif., April 20 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc.
ROCKVILLE, Md. and EXTON, Pa., March 25 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc.
CALGARY, March 12 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.
66% of evaluable heavily-pretreated patients in the high dose groups achieved disease stabilization. ProLindac was well tolerated overall. DALLAS, March 5 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC.
CALGARY, March 4 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today reported its financial results for the year ended December 31, 2008. "In 2008, we selected our first pivotal program for REOLYSIN(R)," said Dr.
- Positive results for first Albuferon(R) Phase 3 trial announced in December 2008; data from second trial expected March 2009 - - Phase 3 trials of darapladib for cardiovascular disease and Syncria(R) for type 2 diabetes initiated by GlaxoSmithKline (GSK) - - $106 million of convertible debt repurchased for $50 million in cash - - 2009 revenue expected to grow to $250 million; at least $150 million from delivery of ABthrax(TM) to Strategic National Stockpile - ROCKVILLE, Md., Feb.
EUSAPharma (formerly Cytogen) Posts Positive Phase I Report from Trial of Quadramet in Combination with Velcade for the Treatment of Relapsed or Refractory Multiple Myeloma. LOS ANGELES, Feb.
--Preliminary Data from Ongoing Study Shows Seven of 14 Evaluable Patients Achieved Objective Tumor Response by the End of Two Treatment Cycles-- --Bavituximab Has Now Produced Positive Early Results in All Three Ongoing Phase II Combination Therapy Cancer Trials-- TUSTIN, Calif., Feb.
- A serpent whose bite was fabled to produce intense thirst.